Viking TherapeuticsVKTX
About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Employees: 34
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
72% more repeat investments, than reductions
Existing positions increased: 174 | Existing positions reduced: 101
68% more call options, than puts
Call options by funds: $360M | Put options by funds: $215M
50% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 62
33% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 8 (+2) [Q3]
20% more capital invested
Capital invested by funds: $4.31B [Q2] → $5.16B (+$851M) [Q3]
8% more funds holding
Funds holding: 385 [Q2] → 416 (+31) [Q3]
0.75% more ownership
Funds ownership: 73.73% [Q2] → 74.48% (+0.75%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 79 / 384 met price target | 141%upside $102 | Buy Reiterated | 20 Dec 2024 |
Piper Sandler Biren Amin 15% 1-year accuracy 3 / 20 met price target | 75%upside $74 | Overweight Initiated | 2 Dec 2024 |
B. Riley Securities Mayank Mamtani 35% 1-year accuracy 8 / 23 met price target | 158%upside $109 | Buy Initiated | 22 Nov 2024 |
Oppenheimer Jay Olson 20% 1-year accuracy 20 / 102 met price target | 227%upside $138 | Outperform Reiterated | 25 Sept 2024 |
Financial journalist opinion
Based on 31 articles about VKTX published over the past 30 days